enzalutamide
XTANDI
Regulators in European have given the green light to Astellas Pharma and Medivation’s oral prostate cancer drug Xtandi.
Specifically, the European Commission has approved Xtandi (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy. The thumbs-up comes a couple of months after the European Medicines Agency’s Committee for Human Medicinal Productsissued a positive recommendation on the treatment….. READ ALL AT
http://www.pharmatimes.com/Article/13-06-24/Astellas_Xtandi_approved_in_EU_for_prostate_cancer.aspx
Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer. Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine. Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth. In August of 2012, the U.S. Food and Drug Administrationapproved enzalutamide for the treatment of castration-resistant prostate cancer.
Enzalutamide was discovered by Charles Sawyers who is now at Memorial Sloan–Kettering Cancer Center and Michael Jung at UCLA.
A model of the interaction between the prostate cancer drug enzalutamide and the androgen receptor
Reblogged this on Med.Chem in Nepal.
Reblogged this on MEDCHEMEGYPT.
Reblogged this on MedChemHot.Pakistan.
Reblogged this on MedCheminSingapore by Sushma Wang.
Reblogged this on MED.CHEM in BURMA.
Reblogged this on MedCheminAustralia.
Reblogged this on MariaGairos–DRUGS.
Reblogged this on Organic Reactions in Medchem.
Reblogged this on GREEN MED CHEMISTRY.
Reblogged this on GREEN MED CHEMISTRY.